- Home
- HY vs KROS Comparison
HY vs KROS Comparison
Compare HY & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HY
- KROS
- Stock Information
- Founded
- HY 1991
- KROS 2015
- Country
- HY United States
- KROS United States
- Employees
- HY N/A
- KROS N/A
- Industry
- HY Construction/Ag Equipment/Trucks
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- HY Industrials
- KROS Health Care
- Exchange
- HY Nasdaq
- KROS Nasdaq
- Market Cap
- HY 640.4M
- KROS 565.0M
- IPO Year
- HY N/A
- KROS 2020
- Fundamental
- Price
- HY $34.20
- KROS $16.18
- Analyst Decision
- HY Strong Buy
- KROS Buy
- Analyst Count
- HY 1
- KROS 14
- Target Price
- HY $70.00
- KROS $20.67
- AVG Volume (30 Days)
- HY 58.6K
- KROS 1.3M
- Earning Date
- HY 11-04-2025
- KROS 11-05-2025
- Dividend Yield
- HY 4.16%
- KROS N/A
- EPS Growth
- HY N/A
- KROS N/A
- EPS
- HY 0.15
- KROS 1.57
- Revenue
- HY $3,913,600,000.00
- KROS $246,718,000.00
- Revenue This Year
- HY N/A
- KROS $6,657.47
- Revenue Next Year
- HY $0.23
- KROS N/A
- P/E Ratio
- HY $225.53
- KROS $10.29
- Revenue Growth
- HY N/A
- KROS 37798.31
- 52 Week Low
- HY $31.06
- KROS $9.12
- 52 Week High
- HY $58.72
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- HY 37.64
- KROS 61.45
- Support Level
- HY $31.06
- KROS $14.86
- Resistance Level
- HY $36.38
- KROS $15.30
- Average True Range (ATR)
- HY 1.38
- KROS 0.57
- MACD
- HY -0.23
- KROS 0.13
- Stochastic Oscillator
- HY 43.18
- KROS 69.73
About HY Hyster-Yale Materials Handling Inc.
Hyster Yale Inc designs, engineers, manufactures, sells and services a comprehensive line of lift trucks, attachments, aftermarket parts and technology solutions marketed globally under the Hyster and Yale brand names. The Company has five segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni) and Nuvera Fuel Cells, LLC (Nuvera). Majority of revenue is from Lift Trucks. geographically operates in America, EMEA, JAPIC, maximum revenue from America.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.